Focus on Deepening Relationships With Transplant Community Ahead of Iomab-B Phase 3 Trial
NEW YORK, NY--(February 16, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium") is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that key clinical and business development personnel will be attending the annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT), referred to as the BMT Tandem Meetings.
Sandesh Seth, Executive Chairman at Actinium Pharmaceuticals, said, "Actinium's lead program, Iomab-B, is the only therapy of its kind and is intended to be an induction and conditioning agent for relapsed and refractory Acute Myeloid Leukemia patients prior to a bone marrow transplant. The BMT Tandem Meetings are invaluable to Actinium and given the upcoming pivotal Phase 3 trial for Iomab-B, we are particularly excited for our conference agenda at this year's annual meetings."
The BMT Tandem Meetings are being held on February 18 - 22, 2016 at the Hawaii Convention Center in Honolulu, Hawaii. Actinium has planned numerous clinical development and market activities at this meeting, which is the largest gathering of its type in the transplant community that are designed to facilitate the initiation of clinical trial sites and recruitment efforts at these centers for the upcoming Iomab-B trial. In addition, to its educational efforts at the meeting, the Company will enhance its outreach via networking events and a marketing presence in the exhibition area. In addition, the Scientific Advisory Board will also hold a meeting that will be focused on the upcoming, pivotal trial for Iomab-B.
Felix Garzon, M.D., Ph.D., Senior Vice President, Head of Clinical Development at Actinium Pharmaceuticals, said, "The BMT Tandem Meetings will be foundational to our upcoming pivotal Phase 3 Iomab-B clinical trial. We look forward to the many interactions we will be having with the transplant community at these meetings."
About the BMT Tandem Meetings
The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT). Investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators, and allied health professional attendees benefit from the full scientific program that addresses the most timely issues in hematopoietic cell transplantation.
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Senior Director, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer